May 10th 2024
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
May 9th 2024
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
May 8th 2024
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
Your daily dose of the clinical news you may have missed.
May 2nd 2024
Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.
7 RSV Myths and Facts: Prepare for the New Wave of Misinformation
RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.
RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Daily Dose: Delay Before Start of Triple Therapy Raises Risk for COPD Exacerbations
Your daily dose of clinical news you may have missed.
Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis
IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.
High-dose Influenza Vaccine Consistently More Effective vs Standard-dose in Older Adults: Meta-analysis
The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.
COPD: Delay Before Start of Triple Therapy May Increase Risk for Exacerbations
CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.
AAFP Tips on Getting Shots into Arms this Flu Season with Sterling Ransone, Jr, MD
AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.
Tezepelumab Reduced Exacerbations in Severe, Uncontrolled Asthma, Regardless of Number of Additional Controller Medications
CHEST 2022. Tezepelumab significantly reduced AAER and improved lung function in patients taking 1, 2, or ≥3 long-acting β-agonists in addition to ICS.
GSK Announces Positive Pivotal Phase 3 Data for Adult RSV Vaccine Candidate
The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.
COPD: Pulmonary Rehab is Effective Regardless of Inhaled Triple Therapy Use
In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.
Primary Care Can Help Restore US Antibiotic Stewardship, Starting with Flu Shots
Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.
Pfizer Reports Positive Topline Phase 3 Data for Bivalent RSV Vaccine in Older Adults
Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.
Delay in IPF Diagnosis Led to Decreased Progression-free Survival, Increased Hospitalization
A real-world study found that a delay in diagnosis of 1 year or more was particularly detrimental to patients with mild disease at time of diagnosis.
Inhaler Education with Teach-to-Goal Methods Improved Technique Among Older Adults with Asthma, COPD
Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.
Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data
For patients with chronic sinusitis, disease exacerbations often require use of antibiotics and steroids, in addition to medical office visits, all of which impact quality of life.
Continuity of Care for Asthma, COPD Patients Could Improve Survival, Cut Costs
When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.
Influenza, PPSV23 Vaccines May Reduce Risk for COPD Exacerbations, Hospitalizations
In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.
Glycopyrrolate/formoterol found Noninferior to Tiotropium/formoterol for Improving COPD Symptoms
Authors of this first study to compare the combinations head-to-head suggest that the glycopyrrolate combination is appropriate for long-term COPD management.
Juul Ban Prompts Praise from Physician Organizations
The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.
Patients with Moderate or Severe Asthma Benefit from High-intensity Interval Training, Study Finds
New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.
FDA Grants EUA for At-home Triple Test: COVID-19, Influenza, RSV
The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.
Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.
Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.
Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.
Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.
Adults with Asthma Found at Higher Risk for Obesity in International Study
The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.
Pulmonary Rehab Improves Lung Function, QOL in Asthma-COPD Overlap Plus Obesity
Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.
Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities
Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.